Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Chemistry, Medicinal
Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim, Aysegul Ozen, Emanuele Perola, John Hsieh, Victoria Brown, Kristina Fetalvero, Andrew Garner, Zhuo Zhang, Faith Stevison, Rich Woessner, Jatinder Singh, Yoav Timsit, Caitlin Kinkema, Clare Medendorp, Christopher Lee, Faris Albayya, Alena Zalutskaya, Stefanie Schalm, Thomas A. Dineen
Summary: While EGFR tyrosine kinase inhibitors have revolutionized the treatment of NSCLC, the development of resistance mutations remains a challenge. This study introduces a novel reversible inhibitor, BLU-945, that shows promising activity against different resistance mutations. Clinical trials are currently underway to evaluate its efficacy and safety.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Medicine, Research & Experimental
Hui Hua, Jiajia Zeng, Haixin Xing, Yuxin He, Linyu Han, Nasha Zhang, Ming Yang
Summary: This study systematically evaluated the role of genetic variants in A-to-I editing genes on the prognosis of NSCLC patients receiving EGFR-TKIs therapy. The researchers identified several SNPs in the ADAR gene that were significantly associated with patient prognosis and found that silencing ADAR enhanced the sensitivity of NSCLC cells to gefitinib. These findings highlight the importance of A-to-I RNA editing in drug resistance and suggest ADAR as a potential therapeutic target for unresectable NSCLC.
Article
Oncology
Jung Hee Cho, Yeon-Mi You, Han Koo, Dong Chul Lee, Young Il Yeom, Kyung Chan Park
Summary: This study identified LPIN1 as a key factor in regulating gefitinib resistance in EGFR-mutant NSCLC cells, and found that LPIN1 expression was induced following gefitinib treatment, leading to increased lipid droplet formation and activation of protein kinase C delta and nuclear factor kappa B. Targeting LPIN1 was shown to synergistically inhibit tumor growth, suggesting a potential effective strategy for preventing TKI resistance in NSCLC patients.
Article
Multidisciplinary Sciences
Liangkun You, Xinnan Zheng, Danchen Deng, Hongming Pan, Weidong Han
Summary: Patients with EGFR L858R mutation treated with anti-angiogenic therapy had a significantly prolonged overall survival compared to those who had not received the treatment. The therapy also showed potential to improve overall survival in patients with liver and brain metastases.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
James Chih-Hsin Yang, Yuichiro Ohe, Chao -Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Janne, Ryan J. Hartmaier, Myung Ju Ahn
Summary: The combination of osimertinib and selumetinib showed promising antitumor activity and tolerability in patients with MET-negative, EGFRm advanced NSCLC who had progressed on previous EGFR-TKI treatment.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Carolin Selenz, Anik Compes, Marieke Nill, Sven Borchmann, Margarete Odenthal, Alexandra Florin, Johannes Braegelmann, Reinhard Buettner, Lydia Meder, Roland T. Ullrich
Summary: EGFR inhibition promotes immune cell infiltration in the tumour microenvironment and enhances response to immune checkpoint inhibitors in EGFR-driven lung cancer.
Article
Multidisciplinary Sciences
Mari Tone, Kota Iwahori, Takayuki Shiroyama, Shinji Futami, Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh
Summary: Minocycline administration in NSCLC patients treated with first-line EGFR-TKIs was found to correlate with longer PFS and OS, independent of skin rash. This retrospective analysis suggests that minocycline may have a positive impact on the treatment outcomes of EGFR-mutant NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Hui Deng, Qian Lei, Chengdi Wang, Zhoufeng Wang, Hai Chen, Gang Wang, Na Yang, Dan Huang, Quanwei Yu, Mengling Yao, Xue Xiao, Guonian Zhu, Cheng Cheng, Yangqian Li, Feng Li, Panwen Tian, Weimin Li
Summary: In this study, the authors present a fluorescence-activated cell sorting assay to identify activating EGFR mutations in lung cancer patients and demonstrate its utility in predicting response to EGFR-tyrosine kinase inhibitors.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Yen-Hsiang Huang, Gee-Chen Chang
Summary: Strong expressions of PD-L1 in treatment naive advanced EGFR-mutant NSCLC patients were associated with poor prognoses in those undergoing treatment with osimertinib as first-line therapy.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Hyoung-oh Jeong, Hayoon Lee, Hyemin Kim, Jinho Jang, Seunghoon Kim, Taejoo Hwang, David Whee-Young Choi, Hong Sook Kim, Naeun Lee, Yoo Mi Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Semin Lee, Se-Hoon Lee
Summary: The study found that specific cell types such as lung epithelial precursor cells and transitional effector T cells, as well as an immunosuppressive microenvironment, were enriched in the MPE of EGFR TKI-resistant patients, potentially associated with their response to TKI therapy.
Review
Medicine, General & Internal
Tai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, Chiou-Mei Wu, Kuan-Li Wu, Chia-Yu Kuo, Po-Ju Wei, Chin-Ling Chen, Hui-Lin Liu, Jen-Yu Hung, Chih-Jen Yang, Inn-Wen Chong
Summary: Patients with advanced non-small cell lung cancer (NSCLC) who have susceptible epidermal growth factor receptor (EGFR) mutations and receive combination treatment with EGFR tyrosine kinase inhibitors (TKIs) and anti-angiogenic agents show better progression-free survival (PFS) outcomes, especially among patients with a smoking history or those treated with erlotinib-based therapy. Combination therapy significantly prolongs PFS regardless of ethnicity.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Article
Multidisciplinary Sciences
Piyada Sitthideatphaiboon, Chinachote Teerapakpinyo, Krittiya Korphaisarn, Nophol Leelayuwatanakul, Nopporn Pornpatrananrak, Naravat Poungvarin, Poonchavist Chantranuwat, Shanop Shuangshoti, Chatchawit Aporntewan, Wariya Chintanapakdee, Virote Sriuranpong, Chanida Vinayanuwattikun
Summary: This study explored the clinical factors and molecular characteristics of de novo EGFR TKI resistance in advanced non-small cell lung cancer. The amplification of CDK4/6 was found to be associated with de novo resistance and could serve as a predictive biomarker.
SCIENTIFIC REPORTS
(2022)
Article
Pharmacology & Pharmacy
Geunho Choi, Daegeun Kim, Junehwan Oh
Summary: This study utilized artificial intelligence to discover potential drugs that can overcome acquired resistance in lung cancer patients, reducing the limitations of the current drug discovery process.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Alessio Cortellini, Marcello Tiseo, Giuseppe L. Banna, Federico Cappuzzo, Joachim G. J. Aerts, Fausto Barbieri, Raffaele Giusti, Emilio Bria, Diego Cortinovis, Francesco Grossi, Maria R. Migliorino, Domenico Galetta, Francesco Passiglia, Daniele Santini, Rossana Berardi, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alessandro Tuzi, Alain Gelibter, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Stefania Gori, Michele De Tursi, Giovanni Mansueto, Federica Zoratto, Matteo Santoni, Marianna Tudini, Erika Rijavec, Marco Filetti, Annamaria Catino, Pamela Pizzutilo, Luca Sala, Fabrizio Citarella, Russano Marco, Mariangela Torniai, Luca Cantini, Giada Targato, Vincenzo Sforza, Olga Nigro, Miriam G. Ferrara, Ettore D'Argento, Sebastiano Buti, Paola Bordi, Lorenzo Antonuzzo, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Cinzia Baldessari, Luigi Della Gravara, Maria Giovanna Dal Bello, Robert A. Belderbos, Paolo Bironzo, Simona Carnio, Serena Ricciardi, Alessio Grieco, Alessandro De Toma, Claudia Proto, Alex Friedlaender, Ornella Cantale, Biagio Ricciuti, Alfredo Addeo, Giulio Metro, Corrado Ficorella, Giampiero Porzio
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2020)
Letter
Oncology
Lorenza Landi, Rossella Bruno, Gabriella Fontanini, Federico Cappuzzo
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Alba A. Brandes, Andrea Ardizzoni, Fabrizio Artioli, Federico Cappuzzo, Luigi Cavanna, Giovanni Luca Frassineti, Antonio Frassoldati, Francesco Leonardi, Giuseppe Longo, Antonio Maestri, Davide Tassinari, Enrico Franceschi, Vincenzo Di Nunno, Carmine Pinto
Meeting Abstract
Oncology
H. West, F. Cappuzzo, M. Reck, T. Mok, R. M. Jotte, M. Nishio, E. Kim, S. Morris, G. Shankar, W. Zou, D. Shames, M. McCleland, M. A. Socinski
ANNALS OF ONCOLOGY
(2020)
Meeting Abstract
Oncology
M. Pagano, G. L. Ceresoli, P. A. Zucali, G. Pasello, M. C. Garassino, F. Grosso, M. Tiseo, H. J. Soto Parra, F. Zanelli, F. Cappuzzo, F. Grossi, F. De Marinis, P. Pedrazzoli, C. Bonelli, A. Berselli, N. Normanno, C. Pinto
ANNALS OF ONCOLOGY
(2020)
Article
Oncology
Maria Pagano, Luca Giovanni Ceresoli, Paolo Andrea Zucali, Giulia Pasello, Marina Garassino, Federica Grosso, Marcello Tiseo, Hector Soto Parra, Francesca Zanelli, Federico Cappuzzo, Francesco Grossi, Filippo De Marinis, Paolo Pedrazzoli, Roberta Gnoni, Candida Bonelli, Federica Torricelli, Alessia Ciarrocchi, Nicola Normanno, Carmine Pinto
Review
Oncology
Daniele Marinelli, Raffaele Giusti, Marco Mazzotta, Marco Filetti, Eriseld Krasniqi, Laura Pizzuti, Lorenza Landi, Silverio Tomao, Federico Cappuzzo, Gennaro Ciliberto, Maddalena Barba, Patrizia Vici, Paolo Marchetti
Summary: Glucocorticoids play a crucial role in managing immune-related adverse events and symptoms in cancer patients. The purpose of glucocorticoid administration may impact the survival outcomes of cancer patients undergoing immune-checkpoint inhibitor treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Letter
Oncology
Raul Pellini, Flaminia Campo, Domenico Sergi, Federico Cappuzzo
Article
Multidisciplinary Sciences
Lorenza Landi, Claudia Ravaglia, Emanuele Russo, Pierluigi Cataleta, Maurizio Fusari, Andrea Boschi, Diana Giannarelli, Francesca Facondini, Ilaria Valentini, Ilaria Panzini, Luigi Lazzari-Agli, Paolo Bassi, Elisa Marchionni, Rossella Romagnoli, Raffaella De Giovanni, Marina Assirelli, Federica Baldazzi, Fabio Pieraccini, Giovanna Rametta, Lucia Rossi, Luca Santini, Ivana Valenti, Federico Cappuzzo
SCIENTIFIC REPORTS
(2020)
Review
Oncology
Lorenza Landi, Federico Cappuzzo
TRANSLATIONAL LUNG CANCER RESEARCH
(2020)
Article
Oncology
Maddalena Barba, Eriseld Krasniqi, Laura Pizzuti, Marco Mazzotta, Daniele Marinelli, Greta Giuliano, Francesca Sofia Di Liso, Federico Cappuzzo, Lorenza Landi, Silverio Tomao, Gennaro Ciliberto, Patrizia Vici
Summary: The COVID-19 pandemic has led to significant changes in the management of cancer patients worldwide, including reduced screening, delayed surgeries and radiotherapy, as well as dose reductions or delays in systemic therapy administration, such as CDK 4/6 inhibitors.
Review
Medicine, General & Internal
Eriseld Krasniqi, Maddalena Barba, Aldo Venuti, Laura Pizzuti, Federico Cappuzzo, Lorenza Landi, Silvia Carpano, Paolo Marchetti, Alice Villa, Enrico Vizza, Greta Giuliano, Marco Mazzotta, Daniele Marinelli, Sandra Gnignera, Cristina Vincenzoni, Vincenzo Stranges, Domenico Sergi, Antonio Giordano, Federica Tomao, Marcello Maugeri-Sacca, Giuseppe Sanguineti, Francesca Sofia Di Lisa, Silverio Tomao, Gennaro Ciliberto, Patrizia Vici
Summary: HPVs are linked to cervical and oropharyngeal cancers, and circulating HPV DNA serves as a potential biomarker for clinical management. Specific and minimally invasive tests can enable early detection and treatment monitoring, with innovative techniques enhancing the detection rate of serum HPV DNA.
JOURNAL OF CLINICAL MEDICINE
(2021)
Meeting Abstract
Oncology
B. Melosky, E. Laack, K. Kambartel, M. Haentschel, M. Bennetts, D. Nickens, J. Brinkmann, A. Kayser, M. Moran, F. Cappuzzo
JOURNAL OF THORACIC ONCOLOGY
(2021)
Meeting Abstract
Oncology
D. R. Spigel, D. Rodriguez-Abreu, F. Cappuzzo, V. Velcheti, A. K. Ganti, D. Johnson, R. Govindan, S. Antonia, B. Besse, M. Altan, M. Edelman, S. Ramalingam, E. Felip, S. Gadgeel, O. Juan-Vidal, A. Gupta, S. Currie, W. Lin, M. Tagliaferri, M. Reck
JOURNAL OF THORACIC ONCOLOGY
(2021)
Meeting Abstract
Respiratory System
M. Reck, R. Jotte, F. Cappuzzo, T. Mok, H. West, M. Nishio, V. A. Papadimitrakopoulou, F. Orlandi, D. Stroyakovskii, C. Thomas, N. Nogami, F. Barlesi, A. Lee, G. Shankar, W. Yu, M. Ballinger, I Bara, A. Sandler, M. Socinski